ArticleTanaffos2023
Trends in Epidemiology and Outcome of Small Cell Lung Cancer over 10 Years at Tertiary Cancer Care Center in Iran.
Article in Tanaffos, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is the leading cause of cancer death. Among different lung cancer histopathologies, small cell lung cancer (SCLC) has been known to be the most aggressive and lethal nature. This study analyzed the epidemiological characteristics, outcomes, and trends of SCLC at a tertiary cancer care center in Iran. Materials and Methods: Retrospectively collected demographic characteristics and survival outcome data on histologically proven SCLC patients during 2009-2019 at the National Research Institute of Tuberculosis and Lung Disease (NRITLD) were reviewed. Results: In a study of 334 SCLC patients, there were more male patients than female, with a ratio of 2.5 to 1, and the mean age at diagnosis was 58.36 years. While gender distribution and smoking status among women remained consistent over the study period, there was a significant increase in male smokers (P<0.001). Female patients were diagnosed at younger age and had a significantly lower proportion of smokers compared to males (P<0.016). The mean and median overall survival were 10.9 and 8.2 months, with one-, two-, and three-year survival rates of 21%, 10%, and 3% respectively. Younger patients and females had significantly higher survival rates. In both uni/multivariate analyses, only age < 58 years and female gender were significantly associated with longer survival. Conclusion: The relatively unchanged trend of SCLC in our series suggests that further research on prevention strategies especially smoking cessation, early detection, and new treatment options is urgently required.
Indexed as
Identifiers
39176146PMC11338514What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.